Welcome to our dedicated page for GSK plc SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GSK plc filings document the company's foreign private issuer disclosures for its American Depositary Shares and ordinary share capital. Recent Form 6-K reports cover product and collaboration announcements, share buyback activity, total voting rights, treasury shares, major holdings notifications and transactions by persons discharging managerial responsibilities.
The filing record also includes governance disclosures such as annual general meeting results, remuneration votes, board elections and shareholder resolutions. These reports connect GSK's biopharma operations with formal disclosures on capital structure, ownership, executive and director dealings, regulatory updates and shareholder governance.
GSK plc reported purchases of its ordinary shares on 11 September 2025 under an existing buyback programme. Acting through Merrill Lynch International, the Company purchased 205,355 ordinary shares at prices ranging from 1,494.50p to 1,518.50p, resulting in an average price shown as 1,509.04p for the aggregated trade line. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since 4 June 2025 the Company has acquired 28,437,562 ordinary shares under the programme. After this transaction GSK will hold 246,571,945 shares in treasury and have 4,068,829,782 ordinary shares in issue (excluding treasury), with total voting rights of 4,068,829,782 and 6.06% of voting rights attributable to treasury shares.
GSK plc reports a share repurchase carried out on 10 September 2025 under its ongoing buyback programme executed by Merrill Lynch International. On that date the Company purchased 213,147 ordinary shares at prices ranging between 1,480.50p and 1,500.00p per share; the aggregated lowest and highest prices reported are 1,480.50p and 1,500.00p respectively.
Since the non-discretionary agreement with the Broker on 4 June 2025, GSK has bought 28,232,207 ordinary shares. Following the latest purchases the Company holds 246,366,590 treasury shares and has 4,069,035,137 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,069,035,137 and treasury-held voting rights of 6.05%.
GSK plc reported small share purchases by several senior executives under its Share Reward Plan. On 2025-09-09, CEO Emma Walmsley acquired 18 ordinary shares, split between partnership and matching shares, at £14.8574 per share on the London Stock Exchange. CFO Julie Brown acquired 16 ordinary shares on the same terms and date.
Additional participants included senior leaders such as the Group General Counsel, heads of corporate development, global supply chain, global affairs, ViiV Healthcare and global health, global communications, and the company secretary. Each of these executives acquired between 16 and 18 ordinary shares, also at £14.8574 per share through the plan.
GSK plc announced that, acting through Merrill Lynch International, it purchased 207,767 ordinary shares on 09 September 2025 at an average price of 1,483.93p per share as part of its ongoing buyback programme.
The purchased shares will be held as Treasury shares. Since the non-discretionary broker agreement dated 4 June 2025, the Company has acquired 28,019,060 ordinary shares in total. After this transaction GSK will hold 246,153,443 ordinary shares in treasury and will have 4,069,248,284 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,069,248,284 and the percentage of voting rights attributable to treasury shares is 6.05%.
GSK plc reported an on-market purchase of 219,116 ordinary shares on 08 September 2025, executed by Merrill Lynch International under the non-discretionary buyback agreement announced 4 June 2025. The shares were bought at prices ranging around 1,460.93p to 1,485.50p per share and will be held as Treasury shares. Since 4 June 2025 the Company has purchased 27,811,293 ordinary shares under the same programme. After this transaction GSK will hold 245,945,676 ordinary shares in treasury and have 4,069,456,051 ordinary shares in issue (excluding Treasury shares), giving a total number of voting rights of 4,069,456,051. The Company states Treasury shares represent 6.04% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its existing buyback programme. On 05 September 2025 the company, acting through Merrill Lynch International, purchased 276,710 ordinary shares at an average price of 1,472.87 pence per share. Since entering the non-discretionary agreement on 4 June 2025 the Company has purchased 27,592,177 ordinary shares. After this purchase GSK will hold 245,726,560 ordinary shares in treasury and will have 4,069,675,167 ordinary shares in issue excluding treasury shares, giving a total number of voting rights of 4,069,675,167. The Company reports that ordinary shares held in treasury represent 6.04% of voting rights following the purchase. Detailed individual trade prices and transaction references for the purchases on 05 September 2025 are provided in the filing.
GSK plc reports that on 04 September 2025 it repurchased 284,800 ordinary shares at an average price of 1,464.66p per share through Merrill Lynch International under its announced buyback programme. The purchased shares will be held as Treasury shares. Since the programme began on 4 June 2025, GSK has bought 27,315,467 ordinary shares. After this transaction the company holds 245,449,850 shares in treasury and has 4,069,946,246 ordinary shares in issue (excluding treasury), giving total voting rights of 4,069,946,246 and treasury-held voting rights of 6.03%.
GSK plc filed a Form 6-K reporting a transaction notification dated September 04, 2025. The filing identifies the security by ISIN GB00BN7SWP63 and discloses an aggregated volume of 10,050 shares. The document provides the transaction date and quantity but does not state the transaction price, the identity of the reporting person or counterparty, or aggregated price information.
GSK plc reports a routine purchase of its ordinary shares under an existing buyback programme. On 03 September 2025 the Company, through Merrill Lynch International, purchased 232,912 ordinary shares at prices in the range shown in the schedule and will hold the purchased shares as Treasury shares. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased 27,030,667 ordinary shares. After this trade the Company holds 245,165,050 ordinary shares in treasury and has 4,070,231,046 ordinary shares in issue (excluding treasury); total voting rights are 4,070,231,046 and the percentage of voting rights attributable to treasury shares is 6.02%.
GSK plc announced that, acting through Merrill Lynch International, it purchased 296,202 ordinary shares of 31 3/4 pence each on 02 September 2025 at prices between 1,440.50p and 1,469.00p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme under a non-discretionary agreement with the broker signed 4 June 2025. Since 4 June 2025 the company has bought 26,797,755 ordinary shares. After this transaction GSK will hold 244,932,138 shares in treasury, have 4,070,463,958 ordinary shares in issue excluding treasury shares, and a total number of voting rights of 4,070,463,958. The company reports that treasury shares represent 6.02% of voting rights following the purchase.